Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301907 | 0.86 | MAOA (0.75) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL29755085 | 0.85 | MAOA (0.74) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL11398007 | 0.83 | MAOA (0.71) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL21327502 | 0.83 | MAOA (0.75) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL20317209 | 0.83 | MAOA (0.71) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL7335491 | 0.83 | MAOA (1.00) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL13712758 | 0.83 | MAOA (0.75) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL132462 | 0.83 | MAOA (1.00) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL30668674 | 0.83 | MAOA (1.00) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL11391221 | 0.82 | MAOA (0.73) | MAOAKDM4EALDH1A1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057037-B | Ultraviolet light-promoted synthesis method of xanthone compound | 浙江工业大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-111057037-A | Ultraviolet light-promoted synthesis method of xanthone compound | 浙江工业大学 | 2020-04-24 | — | — | CN | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2006138528-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
| EP-0005379-B2 | PHOTOSENSITIVE COMPOSITIONS CONTAINING CARBONYLIC HALIDES AS ACTIVATORS | Dynachem Corporation (US) | 1986-06-04 | — | — | EP | disclosed |
| US-4552830-A | UNSATURATED COMPOUND, FREE RADICAL-PRODUCING PHOTOINITIATOR FLUORA COLOR FORMER, PROTON DONOR | DYNACHEM CORPORATION (US) | 1985-11-12 | — | — | US | disclosed |
| US-4343885-A | PHOTORESISTS | DYNACHEM CORPORATION (US) | 1982-08-10 | — | — | US | disclosed |
| EP-0005380-B1 | PHOTOTROPIC PHOTOSENSITIVE COMPOSITIONS CONTAINING A FLUORAN COLORFORMER | Dynachem Corporation (US) | 1982-01-06 | — | — | EP | disclosed |
| EP-0005379-B1 | PHOTOSENSITIVE COMPOSITIONS CONTAINING CARBONYLIC HALIDES AS ACTIVATORS | Dynachem Corporation (US) | 1981-12-23 | — | — | EP | disclosed |
| EP-0005379-A2 | Photosensitive compositions containing carbonylic halides as activators | Dynachem Corporation (US) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005380-A2 | Phototropic photosensitive compositions containing a fluoran colorformer | Dynachem Corporation (US) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | IAPP, SELENOI, SCLY | MAOA 3402/4885KDM4E 4704/4885ALDH1A1 4215/4885 |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | MAOA 555/4885KDM4E 2206/4885ALDH1A1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.